PPHP 2017 Formulary 2017 Step Therapy Criteria

Similar documents
ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

HEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Drug Name (specify drug) Quantity Frequency Strength

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

2016 Step Therapy (ST) Criteria

Step Therapy Requirements. Effective: 1/1/2019

Step Therapy Group. Atypical Antipsychotic Agents

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Pharmacy Management Drug Policy

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

March 2017 Pharmacy & Therapeutics Committee Decisions

Drug Therapy Guidelines

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

Simponi / Simponi ARIA (golimumab)

RHEUMATOID ARTHRITIS DRUGS

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Step Therapy Requirements. Effective: 05/01/2018

Otezla. Otezla (apremilast) Description

Step Therapy Requirements. Effective: 11/01/2018

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

ANTICONVULSANTS. Details

Cimzia. Cimzia (certolizumab pegol) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Cimzia. Cimzia (certolizumab pegol) Description

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Cimzia. Cimzia (certolizumab pegol) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Cosentyx. Cosentyx (secukinumab) Description

DRAFT. Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators

2018 Step Therapy (ST) Criteria

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

Pharmacy Management Drug Policy

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

Stelara. Stelara (ustekinumab) Description

Step Therapy Requirements

Biologics for Autoimmune Diseases

List of Designated High-Cost Drugs

ANTIDIABETIC AGENTS - MISCELLANEOUS

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

2017 Blue Cross and Blue Shield of Louisiana

ANTICONVULSANTS. Details

CIMZIA (certolizumab pegol)

STEP THERAPY CRITERIA

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

ANTIDIABETIC AGENTS - MISCELLANEOUS

Immune Modulating Drugs Prior Authorization Request Form

Step Therapy Criteria

Memorial Hermann Advantage HMO February 2019 Formulary Addendum

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

ACTEMRA (tocilizumab)

Step Therapy Criteria

ANTIDIABETIC AGENTS - MISCELLANEOUS

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

Prescription benefit updates Large group

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Clinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial

HNMC. Interim Guidelines; Final Review and Approval by the P&T Committee Pending

Partners Notice of Change March 2017

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Regulatory Status FDA approved indication: Kineret is an interleukin-1 receptor antagonist indicated for: (1)

Transcription:

ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular Claim will pay automatically for ARISTADA if enrollee has a paid claim for at least a 1 days supply of ABILIFY MAINTENA in the past 365 days. Otherwise, ARISTADA requires a step therapy exception request indicating: (1) history of inadequate treatment response with ABILIFY MAINTENA OR (2) history of adverse event with ABILIFY MAINTENA OR (3) ABILIFY MAINTENA is contraindicated. 1

AUBAGIO Aubagio TABLET 14 MG ORAL Aubagio TABLET 7 MG ORAL CLAIM WILL PAY AUTOMATICALLY FOR Aubagio IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF Gilenya or Tecfidera IN THE PAST 365 DAYS. OTHERWISE, Aubagio REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH Gilenya or Tecfidera, OR (2) HISTORY OF ADVERSE EVENT WITH Gilenya or Tecfidera, OR (3) Gilenya or Tecfidera IS CONTRAINDICATED. 2

DIFICID Dificid TABLET 200 MG ORAL Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 days supply of vancomycin in the past 120 days. Otherwise, Dificid requires a step therapy exception request indicating: (1) history of inadequate treatment response with Vancomycin, OR (2) history of adverse event with Vancomycin, OR (3) Vancomycin is contraindicated. 3

PRADAXA Pradaxa CAPSULE 110 MG Oral Pradaxa CAPSULE 150 MG ORAL CLAIM WILL PAY AUTOMATICALLY FOR Pradaxa IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF Xarelto or Eliquis IN THE PAST 365 DAYS. OTHERWISE, Pradaxa REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH Xarelto or Eliquis, OR (2) HISTORY OF ADVERSE EVENT WITH Xarelto or Eliquis, OR (3) Xarelto or Eliquis IS CONTRAINDICATED. 4

RHEUMATOID ARTHRITIS Actemra SOLUTION 200 MG/10ML Intravenous Actemra SOLUTION 400 MG/20ML Intravenous Actemra SOLUTION 80 MG/4ML Intravenous Actemra Solution Prefilled Syringe 162 MG/0.9ML Subcutaneous Cimzia KIT 2 X 200 MG Subcutaneous Cimzia Prefilled KIT 2 X 200 MG/ML Subcutaneous Cosentyx Sensoready Pen Solution Auto-injector 150 MG/ML Subcutaneous Cosentyx Solution Prefilled Syringe 150 MG/ML Subcutaneous Kineret Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous Orencia ClickJect Solution Auto-injector 125 MG/ML Subcutaneous Orencia Solution Prefilled Syringe 125 MG/ML Subcutaneous Orencia Solution Prefilled Syringe 50 MG/0.4ML Subcutaneous Orencia Solution Prefilled Syringe 87.5 MG/0.7ML Subcutaneous Orencia SOLUTION RECONSTITUTED 250 MG Intravenous Otezla TABLET 30 MG ORAL Otezla Tablet Therapy Pack 10 & 20 & 30 MG Oral Simponi Aria SOLUTION 50 MG/4ML Intravenous Simponi Solution Auto-injector 100 MG/ML Subcutaneous Simponi Solution Auto-injector 50 MG/0.5ML Subcutaneous Simponi Solution Prefilled Syringe 50 MG/0.5ML Subcutaneous Stelara SOLUTION 130 MG/26ML Intravenous Stelara Solution Prefilled Syringe 45 MG/0.5ML Subcutaneous Xeljanz TABLET 5 MG ORAL Claim will pay automatically for Actemra, Cimzia, Cosentyx, Kineret, Orencia, Otezla, Simponi, Stelara, or Xeljanz if enrollee has a paid claim for at least a 1 days supply of Enbrel and Humira in the past 120 days. Otherwise, Actemra, Cimzia, Cosentyx, Kineret, Orencia, Otezla, Simponi, Stelara, or Xeljanz requires a step therapy exception request indicating: (1) history of inadequate treatment response with Enbrel and Humira, OR (2) history of adverse event with Enbrel and Humira, OR (3) Enbrel and Humira is contraindicated. For diagnosis cryopyrinassociated periodic syndromes, Kineret will be approved. For diagnosis of Crohn's disease or Ulcerative Colitis, only Humira needs trial/failure. 5

TRINTELLIX Trintellix TABLET 10 MG ORAL Trintellix TABLET 20 MG ORAL Trintellix TABLET 5 MG ORAL Claim will pay automatically for trintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, trintellix requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants, OR (2) history of adverse event with any 2 generic formulary antidepressants, OR (3) any 2 generic formulary antidepressants are contraindicated. 6

UCERIS Uceris FOAM 2 MG/ACT Rectal Uceris Tablet Extended Release 24 Hour 9 MG Oral Claim will pay automatically for Uceris if enrollee has a paid claim for at least a 1 days supply of any formulary corticosteroid used to treat ulcerative colitis in the past 365 days. Otherwise, Uceris requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with formulary corticosteroid used to treat ulcerative colitis, OR (3) formulary corticosteroid used to treat ulcerative colitis is contraindicated. 7

VEMLIDY Vemlidy TABLET 25 MG ORAL Claim will pay automatically for Vemlidy if enrollee has a paid claim for at least a 1 days supply of lamivudine in the past 365 days. Otherwise, Vemlidy requires a step therapy exception request indicating: (1) history of inadequate treatment response with lamivudine, OR (2) history of adverse event with lamivudine, OR (3) lamivudine is contraindicated. 8

VRAYLAR Vraylar CAPSULE 1.5 MG Oral Vraylar CAPSULE 3 MG Oral Vraylar CAPSULE 4.5 MG Oral Vraylar CAPSULE 6 MG Oral Vraylar Capsule Therapy Pack 1.5 & 3 MG Oral Claim will pay automatically for VRAYLAR if enrollee has a paid claim for at least a 1 days supply of ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE or LATUDA in the past 365 days. Otherwise, Vraylar requires a step therapy exception request indicating any ONE of criteria 1, 2, 3, or 4: (1) history of inadequate treatment response with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE, or LATUDA or (2) history of adverse event with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE, or LATUDA or (3) ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE or LATUDA are contraindicated or (4) For diagnosis of MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER, THE COVERAGE DETERMINATION WILL BE APPROVED WITHOUT REQUIREMENT OF TRIAL AND FAILURE OR CONTRAINDICATION TO LATUDA. 9

XTANDI Xtandi CAPSULE 40 MG ORAL Claim will pay automatically for Xtandi if enrollee has a paid claim for at least a 1 days supply of Zytiga in the past 365 days. Otherwise, Xtandi requires a step therapy exception request indicating: (1) history of inadequate treatment response with Zytiga, OR (2) history of adverse event with Zytiga, OR (3)Zytiga is contraindicated. 10

Alphabetical Listing A Actemra SOLUTION 200 MG/10ML Intravenous... 5 Actemra SOLUTION 400 MG/20ML Intravenous... 5 Actemra SOLUTION 80 MG/4ML Intravenous... 5 Actemra Solution Prefilled Syringe 162 MG/0.9ML Subcutaneous... 5 Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular... 1 Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular... 1 Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular... 1 Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular... 1 Aubagio TABLET 14 MG ORAL... 2 Aubagio TABLET 7 MG ORAL... 2 C Cimzia KIT 2 X 200 MG Subcutaneous... 5 Cimzia Prefilled KIT 2 X 200 MG/ML Subcutaneous... 5 Cosentyx Sensoready Pen Solution Autoinjector 150 MG/ML Subcutaneous... 5 Cosentyx Solution Prefilled Syringe 150 MG/ML Subcutaneous... 5 D Dificid TABLET 200 MG ORAL... 3 K Kineret Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous... 5 O Orencia ClickJect Solution Auto-injector 125 MG/ML Subcutaneous... 5 Orencia Solution Prefilled Syringe 125 MG/ML Subcutaneous... 5 Orencia Solution Prefilled Syringe 50 MG/0.4ML Subcutaneous... 5 Orencia Solution Prefilled Syringe 87.5 MG/0.7ML Subcutaneous... 5 Orencia SOLUTION RECONSTITUTED 250 MG Intravenous... 5 Otezla TABLET 30 MG ORAL... 5 Otezla Tablet Therapy Pack 10 & 20 & 30 MG Oral... 5 P Pradaxa CAPSULE 110 MG Oral... 4 Pradaxa CAPSULE 150 MG ORAL... 4 S Simponi Aria SOLUTION 50 MG/4ML Intravenous... 5 Simponi Solution Auto-injector 100 MG/ML Subcutaneous... 5 Simponi Solution Auto-injector 50 MG/0.5ML Subcutaneous... 5 Simponi Solution Prefilled Syringe 50 MG/0.5ML Subcutaneous... 5 Stelara SOLUTION 130 MG/26ML Intravenous... 5 Stelara Solution Prefilled Syringe 45 MG/0.5ML Subcutaneous... 5 T Trintellix TABLET 10 MG ORAL... 6 Trintellix TABLET 20 MG ORAL... 6 Trintellix TABLET 5 MG ORAL... 6 U Uceris FOAM 2 MG/ACT Rectal... 7 Uceris Tablet Extended Release 24 Hour 9 MG Oral... 7 V Vemlidy TABLET 25 MG ORAL... 8 Vraylar CAPSULE 1.5 MG Oral... 9 Vraylar CAPSULE 3 MG Oral... 9 Vraylar CAPSULE 4.5 MG Oral... 9 Vraylar CAPSULE 6 MG Oral... 9 Vraylar Capsule Therapy Pack 1.5 & 3 MG Oral... 9 X Xeljanz TABLET 5 MG ORAL... 5 Xtandi CAPSULE 40 MG ORAL... 10 11